Cancer public awareness, education, patient empowerment and research. Several cancer types are the focus of the foundation, with special emphasis on prostate cancer. Support for research is focused on development of non-invasive imaging techniques to help provide treatment options for effective cancer control and preservation of quality of life.
The foundation is organized exclusively for charitable, educational and research purposes within the meaning of section 501(c)3 of the IRS code.
Dr. Fabio Almeida discusses C11 Acetate PET/CT Imaging for the detection of prostate cancer recurrance - 2015 mid year PCRI conference. 35 minute presentation followed by Q&A with Dr. Mark Moyad.
In a presentation at a New Mexico Support group September 2013, Dr. Fabio Almeida MD gives an overview of the C11 Acetate PET/CT Imaging for the detection of prostate cancer recurrence.
The Latest in Prostate Cancer Molecular Imaging
Dr. Almeida provides an overview of his presentation at the Radiologic Society of North America (RSNA) annual conference and insights to new technology in this area. Summarized on the PCRI blog.
UroToday International Journal
Early Imaging Improves the Performance of C11-Acetate PET/CT for Recurrent Prostate Adenocarcinoma
Patient ADVOCATES for Advanced Cancer Treatments
Dec. 2012, Vol. 28, No. 4;
Update: Carbon-11 Acetate PET/CT Imaging in Prostate Cancer, Fabio Almeida, Medical Director Arizona Molecular Imaging Center- Phoenix
Detection of intra pelvic versus extra pelvic lesions with Carbon-11 Acetate Positron Emission Tomography/Computed Tomography imaging in the evaluation of recurrent prostate cancer – Interim results from the AMIC-AC-001 clinical study.
- November 2014
Evaluation of recurrent prostate cancer: Performance characteristics of Carbon-11 Acetate PET/CT imaging and Sodium-F18 PET/CT imaging for the detection of bony metastasis.